The antibody contract manufacturing market is projected to grow at an annualized rate of 12%, till 2030
Roots Analysis has done a detailedstudy on Antibody ContractManufacturing Market, 2020-2030, coveringkey aspects of the industry’s evolution and identifying potential future growthopportunities.
To order this 285+ page report, which features100+ figures and 110+ tables, please visit this link
KeyMarket Insights
§ Several companiesworldwide claim to possess the required expertise and infrastructure to offercontract manufacturing services for a variety of antibody-based products.
§ The market landscapeis highly fragmented, featuring the presence of both established players andnew entrants; majority of antibody CMOs claim to operate as one stop shops andhave presence across different regions.
§ In recent years, asteady increase in partnership activity has been observed in this domain; avariety of deals have been inked related to antibodies for use across a numberof different disease indications.
§ At present, theinstalled, global antibody contract manufacturing capacity is estimated to be approximately2.2 million liters, distributed across companies of all sizes worldwide.
§ In order to enhancecore competencies related to this field of research, CMOs are activelyinvesting in upgrading existing infrastructure and expanding their respectivemanufacturing capacities.
§ In fact, ongoingcapability improvement efforts and facility upgrades have led to theestablishment of industry benchmarks, which serve as a standard for new productdevelopment initiatives in this domain.
§ Given that there areseveral antibody-based drug / therapy candidates being evaluated across variousstages of development, the demand for such products is anticipated to risesignificantly over the next decade.
§ Antibody-basedproduct developers are likely to continue to outsource their manufacturingoperations in mid to long term, resulting in a multi-billion growth opportunityfor contract service providers.
Formore information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of an Antibody
3.3. Structure of an Antibody
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies
3.6. Types of Antibodies
3.6.1. Monoclonal Antibodies
3.6.2. Bispecific Antibodies
3.6.3. Polyclonal Antibodies
3.7. Overview of Contract Manufacturing
3.8. Need for Outsourcing in the Biopharmaceutical Industry
3.9. Advantages of Outsourcing Manufacturing Services
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Antibody Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Number of Employees
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Location of Antibody Manufacturing Facilities
4.2.6. Analysis by Type of Antibodies Manufactured
4.2.7. Analysis by Expression Systems Used
4.2.8. Analysis by Regulatory Accreditations / Certifications
4.2.9. Additional Services Offered
5. COMPANY COMPETITIVE ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Input Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: Antibody ContractManufacturers in North America
5.5. Company Competitiveness Analysis: Antibody ContractManufacturers in Europe
5.6. Company Competitiveness Analysis: Antibody ContractManufacturers in Asia
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. AGC Biologics
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Manufacturing Facilities and Capabilities
6.2.4. Future Outlook
6.3. Aldevron
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Manufacturing Facilities and Capabilities
6.3.4. Future Outlook
6.4. AMRI
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Manufacturing Facilities and Capabilities
6.4.4. Future Outlook
6.5. BioXcellence (Boehringer Ingelheim)
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Manufacturing Facilities and Capabilities
6.5.4. Future Outlook
6.6. Emergent BioSolutions
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Manufacturing Facilities and Capabilities
6.6.4. Future Outlook
6.7. Eurofins CDMO
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Manufacturing Facilities and Capabilities
6.7.4. Future Outlook
6.8. FUJIFILM Diosynth Biotechnologies
6.8.1. Company Overview
6.8.2. Service Portfolio
6.8.3. Manufacturing Facilities and Capabilities
6.8.4. Future Outlook
6.9. KBI Biopharma
6.9.1. Company Overview
6.9.2. Service Portfolio
6.9.3. Manufacturing Facilities and Capabilities
6.9.4. Future Outlook
6.10. Lonza
6.10.1. Company Overview
6.10.2. Service Portfolio
6.10.3. Manufacturing Facilities and Capabilities
6.10.4. Future Outlook
6.11. Nitto Avecia Pharma Services
6.11.1. Company Overview
6.11.2. Service Portfolio
6.11.3. Manufacturing Facilities and Capabilities
6.11.4. Future Outlook
6.12. Novasep
6.12.1. Company Overview
6.12.2. Service Portfolio
6.12.3. Manufacturing Facilities and Capabilities
6.12.4. Future Outlook
6.13. Pierre Fabre
6.13.1. Company Overview
6.13.2. Service Portfolio
6.13.3. Manufacturing Facilities and Capabilities
6.13.4. Future Outlook
6.14. Samsung BioLogics
6.14.1. Company Overview
6.14.2. Service Portfolio
6.14.3. Manufacturing Facilities and Capabilities
6.14.4. Future Outlook
6.15. Synthon
6.15.1. Company Overview
6.15.2. Service Portfolio
6.15.3. Manufacturing Facilities and Capabilities
6.15.4. Future Outlook
6.16. Thermo Fisher Scientific
6.16.1. Company Overview
6.16.2. Service Portfolio
6.16.3. Manufacturing Facilities and Capabilities
6.16.4. Future Outlook
7. CASE STUDY:COMPARISON OF SMALL AND LARGE MOLECULES (BIOLOGICS) DRUGS / THERAPIES
7.1. Chapter Overview
7.2. Small Molecule Drugs and Biologics
7.2.1. Comparison of Strengths and Weakness of Small Molecules andBiologics
7.2.2. Comparison of Key Specifications
7.2.3. Comparison of Manufacturing Processes
7.2.4. Comparison of Key Manufacturing related Challenges
8. BENCHMARK ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Region-wise Benchmarking
8.3.1. North America, Peer Group I
8.3.2. North America, Peer Group II
8.3.3. North America, Peer Group III
8.3.4. Europe, Peer Group IV
8.3.5. Europe, Peer Group V
8.3.6. Europe, Peer Group VI
8.3.7. Asia, Peer Group VII
8.3.8. Asia, Peer Group VIII
8.4. Concluding Remarks
9. PARTNERSHIPS
9.1. Chapter Overview
9.2. Partnerships Models
9.3. Antibody Contract Manufacturing: List of Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Antibody
9.3.5. Analysis by Project Scale
9.3.6. Analysis by Focus Therapeutic Area
9.3.7. Most Active Players: Analysis by Number of Partnerships and Typeof Partnership
9.3.8. Geographical Analysis
9.3.8.1. Continent-wise Distribution
9.3.8.2. Country-wiseDistribution
10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Antibody Contract Manufacturers: List of Expansions
10.2.1. Analysis by Year of Expansion
10.2.2. Analysis by Type of Expansion
10.2.3. Analysis by Type of Antibody
10.2.4. Analysis by Location of Manufacturing Facility
10.2.5. Analysis by Location of Manufacturing Facility and Type of Expansion
10.2.6. Analysis of Most Active Players by Number of Expansions
10.2.7. Geographical Analysis
10.2.7.1. Country-wiseDistribution
11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Antibody Contract Manufacturing: Installed Global Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Expression System
11.3.4. Analysis by Location of Manufacturing Facility
11.3.5. Analysis by Geography and Scale of Operation
11.3.6. Analysis by Geography and Company Size
11.4. Concluding Remarks
12. DEMAND ANALYSIS
12.1 Chapter Overview
12.2 Assumptions and Methodology
12.3 Antibody Contract Manufacturing Market: Overall Annual Demand
12.3.1. Analysis by Scale of Operation
12.3.2. Analysis by Geography
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Assumptions and Forecast Methodology
13.3. Overall Antibody Contract Manufacturing Market, 2020-2030
13.4. Antibody Contract Manufacturing Market, 2020-2030: Distributionby Type of Antibody
13.5. Antibody Contract Manufacturing Market, 2020-2030: Distributionby Company Size
13.6. Antibody Contract Manufacturing Market, 2020-2030: Distributionby Scale of Operation
13.7. Antibody Contract Manufacturing Market, 2020-2030: Distributionby Expression System Used
13.8. Antibody Contract Manufacturing Market, 2020-2030: Distributionby Geography
13.8.1. Antibody Contract Manufacturing Market in North America, 2020-2030
13.8.1.1. Antibody ContractManufacturing Market in North America, 2020-2030: Share of Small Companies
13.8.1.2. Antibody ContractManufacturing Market in North America, 2020-2030: Share of Mid-sized Companies
13.8.1.3. Antibody ContractManufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies
13.8.1.4. Antibody ContractManufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.8.1.5. Antibody ContractManufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations
13.8.1.6. Antibody ContractManufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations
13.8.1.7. Antibody ContractManufacturing Market in North America, 2020-2030: Share of Microbial Cell- based Operations
13.8.2. Antibody Contract Manufacturing Market in Europe, 2020-2030
13.8.2.1. Antibody ContractManufacturing Market in Europe, 2020-2030: Share of Small Companies
13.8.2.2. Antibody ContractManufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies
13.8.2.3. Antibody ContractManufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies
13.8.2.4. Antibody ContractManufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.8.2.5. Antibody ContractManufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations
13.8.2.6. Antibody ContractManufacturing Market in Europe, 2020-2030: Share of Mammalian Cell- based Operations
13.8.2.7. Antibody ContractManufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations
13.8.3. Antibody Contract Manufacturing Market in Asia, 2020-2030
13.8.3.1. Antibody ContractManufacturing Market in Asia, 2020-2030: Share of Small Companies
13.8.3.2. Antibody ContractManufacturing Market in Asia, 2020-2030: Share of Mid-sized Companies
13.8.3.3. Antibody ContractManufacturing Market in Asia, 2020-2030: Share of Large / Very Large Companies
13.8.3.4. Antibody ContractManufacturing Market in Asia, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.8.3.5. Antibody ContractManufacturing Market in Asia, 2020-2030: Share of Commercial Scale Operations
13.8.3.6. Antibody ContractManufacturing Market in Asia, 2020-2030: Share of Mammalian Cell-based Operations
13.8.3.7. Antibody ContractManufacturing Market in Asia, 2020-2030: Share of Microbial Cell-based Operations
14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Strengths
14.3. Weaknesses
14.4. Opportunities
14.5. Threats
14.6. Comparison of SWOT Factors
14.7. Concluding Remarks
15. FUTURE OF THE ANTIBODY CMO MARKET
15.1. Chapter Overview
15.2. Outsourcing Activity Anticipated to Witness Significant Growth
15.3. Shift from One-time Contractual Engagements to StrategicPartnerships
15.4. Adoption of New and Innovative Technologies
15.5. Growing Biosimilars Market to Contribute to the Growth of theContract Services Segment
15.6. Capability and Expertise Expansions by CMOs to become One StopShops
15.7. Offshoring Outsourcing Activities to Maximize Profits and ExpandExisting Capacities
15.8. Challenges Faced by both Sponsors and Service Providers
15.9. Concluding Remarks
16. INTERVIEW TRANSCRIPTS
16.1. ChapterOverview
16.2. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
16.3. David C Cunningham, Director Corporate Development, GoodwinBiotechnology
16.4. Claire Otjes, Assistant Marketing Manager, BataviaBiosciences
17. APPENDIX 1: LIST OF ANTIBODY CUSTOM MANUFACTURERS
18. APPENDIX 2: TABULATED DATA
19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
